
CIBC analyst Tal Wooley initiated coverage of Empire Company (EMLAF) with a Neutral rating and C$57 price target The firm view Empire’s story as “one of a large organization trying
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| EMLAF | Empire Co Cl A NV | 36.31 | 0.03 | 0.08% |
| Name | Price | % Change | |
|---|---|---|---|
| $36.31 | +0.08% |

CIBC analyst Tal Wooley initiated coverage of Empire Company (EMLAF) with a Neutral rating and C$57 price target The firm view Empire’s story as “one of a large organization trying

Analyst from TD Cowen maintained a Hold rating on Empire Co Cl A NV and decreased the price target to C$52.00 from C$53.00. analyst has given his Hold rating due

Empire Co Cl A Nv (($TSE:EMP.A)) has held its Q1 earnings call. Read on for the main highlights of the call. Empire Co Cl A Nv struck a decidedly upbeat

Empire Co Cl A NV, the Consumer Defensive sector company, was revisited by a Wall Street analyst yesterday. Analyst Tamy Chen from BMO Capital maintained a Buy rating on the

Scotiabank analyst John Zamparo lowered the firm’s price target on Empire Company (EMLAF) to C$48 from C$50 and keeps a Sector Perform rating on the shares. Trade-down appears to be

Empire Co Cl A Nv (EMP.A) is scheduled to report 1st quarter earnings on 09/10/2026, before the market opens. Regarding Q1 estimates, Wall Street analysts expect Empire Co Cl A

Scotiabank analyst John Zamparo lowered the firm’s price target on Empire Company (EMLAF) to C$50 from C$52 and keeps a Sector Perform rating on the shares. Published first on TheFly

The latest announcement is out from Empire Co Cl A NV ( ($TSE:EMP.A) ). Empire Company Limited and Sobeys Inc. have agreed to acquire nine Morelli’s pharmacies located inside Longo’s

TD Cowen analyst has maintained their neutral stance on EMP.A stock, giving a Hold rating on July 23. analyst has given his Hold rating due to a combination of factors,

Empire Co Cl A NV ( ($TSE:EMP.A) ) has provided an update. PharmaTher has entered a collaboration with KetaMist inventor Dr. Curtis W. Cassidy to advance KetaMist, a proprietary patient-controlled,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 10, 2026Before Open | $8.09B | $0.53 | $5.74B | -0.76 | 53.06 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.